# Semnur Pharmaceuticals, Inc.: overview SMNR · OTC · CIK 1913577 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/smnr.md) · [Financials](/companies/smnr/financials.md) · [Filings](/companies/smnr/filings.md) · [Insiders](/companies/smnr/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.01)](/filings/0001193125-25-277536.md) | not reported | [(0.01)](/filings/0001193125-26-221896.md) | [(0.01)](/filings/0001193125-26-342594.md) | [(0.76)](/filings/0001193125-25-277536.md) | not reported | [(0.02)](/filings/0001193125-26-221896.md) | [(0.02)](/filings/0001193125-26-342594.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | [(0.02)](/filings/0001193125-26-082642.md) | [(0.78)](/filings/0001193125-26-082642.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/smnr/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [GAMMA Investing LLC](/funds/2010235.md) | 2026-06-30 | $58 | 116 | | New +116 | | [RHUMBLINE ADVISERS](/funds/1115418.md) | 2026-06-30 | $15 | 30 | | New +30 | ## Recent filings [All 213 filings](/companies/smnr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-10 | 16:54 ET | [10-Q](/filings/0001193125-26-342594.md) | Quarterly report, period 2026-06-30 | 0001193125-26-342594 | | 2026-07-07 | 10:38 ET | [8-K](/filings/0001193125-26-297085.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-297085 | | 2026-06-25 | 17:03 ET | [8-K](/filings/0001193125-26-283007.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-283007 | | 2026-05-13 | 17:02 ET | [10-Q](/filings/0001193125-26-221896.md) | Quarterly report, period 2026-03-31 | 0001193125-26-221896 | | 2026-04-30 | 16:50 ET | [DEF 14A](/filings/0001193125-26-197655.md) | Proxy statement, period 2026-06-25 | 0001193125-26-197655 | | 2026-04-23 | 16:08 ET | [8-K](/filings/0001193125-26-173690.md) | 1.02 Termination of a material agreement | 0001193125-26-173690 | | 2026-03-17 | 16:13 ET | [8-K](/filings/0001193125-26-110816.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-110816 | | 2026-02-27 | 16:12 ET | [10-K](/filings/0001193125-26-082642.md) | Annual report, period 2025-12-31 | 0001193125-26-082642 | | 2025-12-19 | 16:07 ET | [S-1/A](/filings/0001193125-25-326813.md) | Registration statement, amended | 0001193125-25-326813 | | 2025-12-03 | 16:20 ET | [8-K](/filings/0001193125-25-306757.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-306757 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-082642.md), filed Feb 27, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1913577 - Tickers: SMNR, SMNRW - Exchange: OTC - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.